Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

venetoclax 91Azacitidine 75Cytarabine 68Specimen Handling 45fludarabine 44Biopsy 32Cyclophosphamide 29Daunorubicin 27fludarabine phosphate 25Injections 25Decitabine 25Idarubicin 24Busulfan 20Granulocyte Colony-Stimulating Factor 19Whole-Body Irradiation 18Mycophenolic Acid 18Tacrolimus 17Melphalan 17decitabine and cedazuridine drug combination 16gilteritinib 14Stem Cell Transplantation 14CPX-351 14Mitoxantrone 13Peripheral Blood Stem Cell Transplantation 11Magnetic Resonance Spectroscopy 11Filgrastim 11Etoposide 11Cladribine 11ivosidenib 10revumenib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × TAK-243 × 90 days × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡